Cargando…

The predictive factors of α1-D/A adrenoceptor antagonist, naftopidil, dose increase therapy for male lower urinary tract symptoms caused by benign prostatic hyperplasia: INFORM study

INTRODUCTION: We evaluated the predictive factors which affect the efficacy of naftopidil 50 mg/day therapy and dose increase therapy to administration of 75 mg/day after an initial dose of 50 mg/day. MATERIALS AND METHODS: A total of 92 patients with male lower urinary tract symptoms/benign prostat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tanuma, Yasushi, Tanaka, Yoshinori, Takeyama, Ko, Okamoto, Tomoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5532895/ https://www.ncbi.nlm.nih.gov/pubmed/28794594 http://dx.doi.org/10.4103/UA.UA_23_17

Ejemplares similares

Does prostate volume affect the efficacy of α1D/A: Adrenoceptor antagonist naftopidil?
por: Tanuma, Yasushi, et al.
Publicado: (2016)

Cutoff level of prostate volume to predict the efficacy of α1-D/A adrenoceptor antagonist, naftopidil
por: Tanuma, Yasushi, et al.
Publicado: (2021)

Comparative evaluation of naftopidil and tamsulosin in the treatment of patients with lower urinary tract symptoms with benign prostatic hyperplasia
por: Griwan, Mahavir Singh, et al.
Publicado: (2014)

Naftopidil for the treatment of urinary symptoms in patients with benign prostatic hyperplasia
por: Masumori, Naoya
Publicado: (2011)

The Persistence of Silodosin Monotherapy and the Reasons for Withdrawal from Treatment of Previously Untreated Japanese Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia
por: Tanaka, Yoshinori, et al.
Publicado: (2017)

Search for new α1a-adrenoceptor-selective antagonist for treating lower urinary tract symptoms associated with benign prostatic hyperplasia
por: Khurana, Naval, et al.
Publicado: (2007)

Involvement of magnitude of ambient temperature change in nonspecific effect in perceived placebo effect on lower urinary tract symptoms: study on switching of naftopidil in patients with benign prostatic hyperplasia
por: Morita, Tatsuo, et al.
Publicado: (2013)

Crystal structures, absolute configurations and molecular docking studies of naftopidil enantiomers as α(1D)-adrenoceptor antagonists
por: Xu, Wei, et al.
Publicado: (2017)

The Urinary Tract Microbiome in Male Genitourinary Diseases: Focusing on Benign Prostate Hyperplasia and Lower Urinary Tract Symptoms
por: Kim, Myung Soo, et al.
Publicado: (2021)

Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms: Epidemiology and Risk Factors
por: Parsons, J. Kellogg
Publicado: (2010)

Is Increased Prostatic Urethral Angle Related to Lower Urinary Tract Symptoms in Males with Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms?
por: Park, Yoo Jun, et al.
Publicado: (2012)

The Potential Role of Urinary Microbiome in Benign Prostate Hyperplasia/Lower Urinary Tract Symptoms
por: Yu, Seong Hyeon, et al.
Publicado: (2022)

Current consensus and controversy on the treatment of male lower urinary tract symptoms/benign prostatic hyperplasia
por: Liao, Chun-Hou, et al.
Publicado: (2017)

Current consensus and controversy on the diagnosis of male lower urinary tract symptoms/benign prostatic hyperplasia
por: Lee, Cheng-Ling, et al.
Publicado: (2017)

Lower urinary tract symptoms and benign prostatic hyperplasia: From research to bedside
por: Goel, Apul
Publicado: (2019)

Use of alpha-1 adrenoceptor antagonists in patients who underwent low-dose-rate brachytherapy for prostate cancer - a randomized controlled trial of silodosin versus naftopidil -
por: Tanaka, Nobumichi, et al.
Publicado: (2014)

Clinical Efficacy and Safety of Naftopidil Treatment for Patients with Benign Prostatic Hyperplasia and Hypertension: A Prospective, Open-Label Study
por: Chung, Mun Su, et al.
Publicado: (2017)

Management of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia by general practitioners in Jakarta
por: Matondang, Faisal Abdi, et al.
Publicado: (2014)

Precision medicine in the diagnosis and treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia
por: Chen, Jing-Liang, et al.
Publicado: (2019)

Clinical Feature of Men Who Benefit from Dose Escalation of Naftopidil for Lower Urinary Tract Symptoms: A Prospective Study
por: Mizusawa, Takaki, et al.
Publicado: (2011)

Impact of Intravesical Protrusion of the Prostate in the Treatment of Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia of Moderate Size by Alpha Receptor Antagonist
por: Seo, Yu Mi, et al.
Publicado: (2012)

Relationship Between Chronic Periodontitis and Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia
por: Hyun, Hana, et al.
Publicado: (2021)

Seasonal Variation of Urinary Symptoms in Korean Men with Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia
por: Choi, Ho Chul, et al.
Publicado: (2015)

Efficacy and safety of dutasteride with tadalafil add-on therapy in patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia
por: Gotoh, Daisuke, et al.
Publicado: (2022)

Prescription pattern of alpha-blockers for management of lower urinary tract symptoms/benign prostatic hyperplasia
por: Moon, Hyong Woo, et al.
Publicado: (2018)

The Relationships between Thyroid Hormone Levels and Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia
por: Lee, Jun Ho, et al.
Publicado: (2019)

The effects of statins on benign prostatic hyperplasia and the lower urinary tract symptoms: A Meta-analysis
por: Yang, Xuesong, et al.
Publicado: (2019)

Three-year outcome analysis of alpha 1-blocker naftopidil for patients with benign prostatic hyperplasia in a prospective multicenter study in Japan
por: Masumori, Naoya, et al.
Publicado: (2016)

The Relationship between Depression, Anxiety, Somatization, Personality and Symptoms of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia
por: Koh, Jun Sung, et al.
Publicado: (2015)

Effects of Low-Dose Tamsulosin on Sexual Function in Patients With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia
por: Kim, Sin Wook, et al.
Publicado: (2013)

The prostatic urethral angle can predict the response to alpha adrenoceptor antagonist monotherapy for treating nocturia in men with lower urinary tract symptom: A multicenter study
por: Kim, Byung Hoon, et al.
Publicado: (2016)

Relationship between Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia and Metabolic Syndrome in Korean Men
por: Park, Yeon Won, et al.
Publicado: (2012)

Minimally invasive devices for treating lower urinary tract symptoms in benign prostate hyperplasia: technology update
por: Aoun, Fouad, et al.
Publicado: (2015)

New medical treatments for lower urinary tract symptoms due to benign prostatic hyperplasia and future perspectives
por: Albisinni, Simone, et al.
Publicado: (2016)

Patient-reported ejaculatory function and satisfaction in men with lower urinary tract symptoms/benign prostatic hyperplasia
por: Cho, Min Chul, et al.
Publicado: (2018)

Functional Balance and Gait Characteristics in Men With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia
por: Al-Yahya, Emad, et al.
Publicado: (2019)

Inflammation is a target of medical treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia
por: De Nunzio, Cosimo, et al.
Publicado: (2020)

Efficacy and safety of fexapotide triflutate in outpatient medical treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia
por: Shore, Neal, et al.
Publicado: (2019)

Mobile health: a promising tool for the management of male patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia
por: Creta, Massimiliano, et al.
Publicado: (2023)

Benign prostatic hyperplasia and male lower urinary symptoms: A guide for family physicians
por: Vasanwala, Farhad Fakhrudin, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_mbq237gkml7ip6h1foptf5rl8m